Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature

Invest New Drugs. 2014 Oct;32(5):1048-52. doi: 10.1007/s10637-014-0063-z. Epub 2014 Jan 18.

Abstract

A role for CD20 antibodies in treating prostate cancer has not yet been established. We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / immunology
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antigens, CD20 / immunology*
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Kallikreins / blood
  • Lymphatic Diseases / blood
  • Lymphatic Diseases / drug therapy
  • Lymphatic Diseases / immunology
  • Male
  • Middle Aged
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / immunology
  • Rituximab

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab
  • Kallikreins
  • kallikrein-related peptidase 3, human
  • Prostate-Specific Antigen